Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.82 |
| ▸ | FLT3 | P36888 | 4/20 | 0.80 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.80 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.76 |
| ▸ | MEN1 | O00255 | 8/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.76 |
| ▸ | NPC1 | O15118 | 4/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.74 |
| ▸ | TP53 | P04637 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | MAOB | P27338 | 2/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978577 | 1.00 | ABCB1 (0.82) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| SCHEMBL2874033 | 0.90 | POLH (0.79) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| Trimethylapigenin SCHEMBL29350875 | 0.90 | ABCB1 (1.00) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| Trimethylapigenin SCHEMBL1421585 | 0.90 | ABCB1 (1.00) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| Genkwanin SCHEMBL866123 | 0.89 | FLT3 (1.00) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| Genkwanin SCHEMBL29445006 | 0.89 | FLT3 (1.00) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| SCHEMBL4279323 | 0.88 | ABCB1 (0.80) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| SCHEMBL19129475 | 0.88 | KDM4E (0.72) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| SCHEMBL16894667 | 0.87 | ABCB1 (0.74) | ABCB1FLT3IP6K2MKNK2KDM4E | |
| SCHEMBL22667395 | 0.86 | ABCB1 (0.82) | ABCB1FLT3IP6K2MKNK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-20 | — | — | US | claimed |
| WO-2015161309-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | ZHOU JIA (US) | 2015-10-22 | — | — | WO | claimed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | claimed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | claimed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | claimed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | claimed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | claimed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | claimed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20190307818-A1 | NOVEL ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2019-10-10 | — | — | US | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-9868715-B2 | Apigenin analogs, compositions, and methods related thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| US-20060216251-A1 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2006-09-28 | — | — | US | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | ABCB1 1197/4885FLT3 4497/4885IP6K2 2277/4885 |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | SLC5A2, SLC5A1, SLC5A6 | ABCB1 80/4885FLT3 1420/4885IP6K2 1620/4885 |
| US-20060216251-A1 | Topical formulations and methods of use | CPT1B, SLC25A20, CPT1A | ABCB1 4502/4885FLT3 4875/4885IP6K2 3799/4885 |
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | CBS, CTH, PTGIS | ABCB1 831/4885FLT3 3112/4885IP6K2 3907/4885 |
| US-20190307818-A1 | NOVEL ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | STING1, STAT1, STAT3 | ABCB1 3695/4885FLT3 47/4885IP6K2 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.